Abstract
This study reports the efficacy of prolonged administration of oral etoposide in the treatment of 86 cases with solid tumor, malignant lymphoma and other cancer. The oral etoposide used was the Lastet capsule (Las-c). An overall response rate (RR) of 62.8% was achieved with CR rate being 23.3% and PR rate 39.5%. Different combination chemotherapy regimens led to different response rates but no significant difference was found. The Las-C containing regimens used in this study have not caused any serious side effects.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
